Inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel
US7304090B2 · kind B2 · utility
5Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2001 |
| Grant date | Dec 4, 2007 |
| Priority date | — |
| Expiry date | Jul 12, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Fluorescein and derivatives have use in the treatment of a disease of a living animal body, including human, which disease is responsive to the inhibition of the cystic fibrosis transmembrane conductance regulator chloride channels, for instance polycystic kidney disease and secretory diarrhoea.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.